Jeffrey F. Scherrer, Ph.D., from Saint Louis University School of Medicine, and colleagues used Veterans Health Administration medical record data (2000 to 2015) to identify 73,761 African-American and white patients (aged ≥50 years) who were free of dementia and diabetes medications at baseline (2000 and 2001) but subsequently initiated metformin or sulfonylurea monotherapy. When controlling for other variables, the researchers found...
Tag: <span>Metformin</span>
Post
Is a diabetes drug the key to aggressive breast cancer?
By Ana Sandoiu Fact checked by Paula Field New research finds that the diabetes drug metformin changes stem cancer cells in a way that makes them easier to target with a new form of treatment. The findings could help treat triple-negative breast cancer, which is particularly aggressive. Triple-negative breast cancer is an aggressive form of breast cancer...
Post
Metformin may cut mortality risk in post-pancreatitis diabetes
Jaelim Cho, M.D., M.P.H., from the University of Auckland in New Zealand, and colleagues used nationwide pharmaceutical dispensing data (from 2006 to 2015) linked to hospital discharge data to identify 1,862 individuals with PCRD or PPDM. The researchers found that in individuals with PCRD, ever users of metformin (adjusted hazard ratio [aHR], 0.54) and ever users of insulin (aHR,...
Post
Metformin may help patients maintain weight loss long-term
by American College of Physicians In the Diabetes Prevention Program (DPP) clinical trial and its long-term follow-up study, among the persons who lost at least 5 percent of their body weight during the first year, long-term maintenance of weight loss was more likely if they had been assigned to treatment with metformin than with placebo or lifestyle intervention. Being older and losing a greater amount of weight in the...
Post
How an existing diabetes drug controls pancreatic cancer
New research suggests that targeting a particular cell signaling pathway with the diabetes drug metformin might offer a way to stop the progression and spread of pancreatic cancer. The study — which was led by Rutgers Cancer Institute of New Jersey in New Brunswick — is to feature at the 2018 annual meeting of the American...
Post
Metformin shows promise as a potential treatment for fragile X syndrome
An inherited form of intellectual disability called fragile X may be treatable with metformin, the most widely used type 2 diabetes drug. This was the conclusion that researchers came to after studying the social, behavioral, and biological effects of metformin in a mouse model of fragile X. Research has shown that metformin, a drug used...